Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Aastrom Biosciences |
---|---|
Information provided by: | Aastrom Biosciences |
ClinicalTrials.gov Identifier: | NCT00797550 |
The hypothesis is that Aastrom TRC autologous bone marrow tissue "grafts" can be safely used to promote bone healing as part of a single level posterolateral spine fusion surgical procedure.
Condition | Intervention | Phase |
---|---|---|
Single Level Posterolateral Spinal Fusion |
Procedure: Bone Repair Cells (BRCs) with allogeneic, demineralized bone matrix Procedure: Spine fusion with autologous bone graft |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion |
Enrollment: | 2 |
Study Start Date: | April 2006 |
Study Completion Date: | October 2008 |
Primary Completion Date: | August 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Control: Active Comparator
The Control arm of the study will receive traditional bone autograft.
|
Procedure: Spine fusion with autologous bone graft |
Treatment: Experimental
The Treatment arm of the study will receive standard of care therapy, a bone marrow aspiration and single level posterolateral spinal fusion between L1 to S1 levels with implantation of TRC product.
|
Procedure: Bone Repair Cells (BRCs) with allogeneic, demineralized bone matrix
BRCs will be administered during spine fusion surgery
|
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Rationale for Exclusion of Certain Study Candidates
Bisphosphonate Therapy
Responsible Party: | Aastrom Biosciences, Inc. ( Elmar Burchardt, MD, PhD ) |
Study ID Numbers: | ABI-55-0509-1 |
Study First Received: | November 24, 2008 |
Last Updated: | November 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00797550 History of Changes |
Health Authority: | United States: Food and Drug Administration |
posterolateral spine fusion bone graft |